Bleeding Disorder

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
BT524Phase 31 trial
Active Trials
NCT03444324CompletedEst. Nov 2023
Abbott
AbbottABBOTT PARK, IL
1 program
XIENCEN/A1 trial
Active Trials
NCT03355742Completed963Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Biotest PharmaceuticalsBT524
AbbottXIENCE

Clinical Trials (2)

Total enrollment: 963 patients across 2 trials

NCT03444324Biotest PharmaceuticalsBT524

Adjusted Fibrinogen Replacement Strategy

Start: Apr 2018Est. completion: Nov 2023
Phase 3Completed
NCT03355742AbbottXIENCE

XIENCE 28 Global Study

Start: Feb 2018Est. completion: Apr 2020963 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space